A pragmatic randomized controlled trial of standard care versus corticosteroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)
Lucinde R., Abdi A., Orindi B., Mwakio S., Gathuri H., Onyango E., Chira S., Ogero M., Isaaka L., Shangala J., Oginga IN., Wachira A., Manuthu E., Kariuki H., Nyikuli J., Wekesa C., Otedo A., Bosire H., Okoth SB., Ongalo W., Mukabi D., Lusamba W., Muthui B., Kirui N., Adembesa I., Mithi C., Sood M., Ahmed N., Gituma B., Ongaki VB., Giabe M., Omondi C., Ombajo LA., Kagucia W., English M., Hamaluba M., Ochola-Oyier LI., Kamuya D., Bejon P., Agweyu A., Akech S., Etyang AO.
Background Mortality among adults admitted to hospital with community acquired pneumonia in resource-limited settings is high. Recent studies conducted in high-income settings have demonstrated beneficial effects of low-dose corticosteroids in reducing mortality in patients with severe community acquired pneumonia. It is unknown whether these findings apply to low-income settings such as sub-Saharan Africa. This pragmatic randomized-controlled open-label trial will determine the effect of adjunctive low-dose corticosteroids in the management of adults admitted to hospital with community acquired pneumonia on mortality 30-days post-randomization. Methods We will enroll and randomize 2180 patients admitted with a diagnosis of community acquired pneumonia into two arms: the control and intervention arm. Those in the control arm will receive standard care for the treatment of community acquired pneumonia i.e., combination therapy with a beta-lactam and macrolide antibiotic. Those in the intervention arm will receive up to 10-days treatment with low-dose oral corticosteroids in addition to standard care. All participants will be followed up to 30- days post randomization and their final status recorded (alive or dead). Discussion If adjunctive low-dose oral corticosteroids are found to be beneficial, this easily scalable intervention would significantly reduce the currently high mortality associated with community acquired pneumonia. Pan-African Clinical Trials Registry: PACTR202111481740832; ISRCTRN registry: ISRCTN36138594